"Straightforward conjugation of payloads to mAbs under mild reaction conditions"

Publications

LinXis continues to employ chemists and scientists that provide a continuous flow of high impact articles ensuring prior-art and technological exposure of their developments.

A novel Platinum (II) Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin- F Conjugated Trastuzumab January 2017 Sijbrandi JS, Merkul E, Muns JA, Waalboer DCJ, Adamzek K, Bolijn M, Montserrat V, Somsen GW, Hasselberg R, Steverink PJGM, Houthoff HJ, van Dongen GAMS. Cancer Research January 15, 2017
Platinum(II) as bifunctional linker in antibody-drug conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model. May 2015 Waalboer DC, Muns JA, Sijbrandi NJ, Schasfoort RB, Haselberg R, Somsen GW, Houthoff HJ, van Dongen GA. ChemMedChem. 2015
Development of novel ADCs: conjugation of tubulysin-analogues to trastuzumab monitored by dual-radiolabeling. October 2014 Cohen R, Vugts DJ, Visser GWM, Stigter-van Walsum M, Bolijn M, Spiga M, Lazzari P, Shankar S, Sani M, Zanda M, Van Dongen GAMS. Cancer Research. 2014
Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-modal fluorescent/PET imaging. May 2013 Cohen R, Vugts DJ, Stigter-van Walsum M, Visser GWM, Van Dongen GAMS. Nature Protocols. 2013
Immuno-PET: shedding light on clinical antibody development. August 2010 Van Dongen GAMS and Vosjan MJDW. Cancer biotherapy & radiopharmaceuticals. 2010
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. April 2010 Vosjan MJWD, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, Van Dongen GAMS. Nature Protocols. 2010

Publications

A novel Platinum (II) Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin- F Conjugated Trastuzumab

Platinum(II) as bifunctional linker in antibody-drug conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model.

Development of novel ADCs: conjugation of tubulysin-analogues to trastuzumab monitored by dual-radiolabeling.

Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-modal fluorescent/PET imaging.

Immuno-PET: shedding light on clinical antibody development.

Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.